ASGCT 2026: Skylark Bio is developing a gene therapy for the largest cause of pediatric deafness. They have plans to be in the clinic this summer and early data will come by the end of the year
- May 14
- 1 min read
Updated: May 16
President & CEO Jodi Cook describes how Skylark is targeting the GJB2 gene, and the work that has gone into delivering the gene therapy to the right cells in the inner ear and only those cell.
Coverage brought to you by
.png){kind=logo}